Drug Trial Radar · NCT06649331
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Oct 21, 2024
Primary completion
Sep 2026
Study completion Sep 2027
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, phase 2 platform trial. The purpose of this study is to test the safety and effectiveness of the antibody-conjugated drugs (ADCs) in patients with advanced breast cancer who had previously used antibody-conjugated drugs.
Conditions
- Advanced Breast Cancer
- Metastatic Breast Cancer
- Triple Negative Breast Cancer (TNBC)
- HER2-negative Breast Cancer
- Breast Cancer
Interventions
SHR-A1811Drug
A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.
SHR-A1921Drug
A TROP2-directed ADC, via intravenous (into the vein) infusion per protocol.
SHR-A2009Drug
A HER3-directed ADC, via intravenous (into the vein) infusion per protocol.
SHR-A2102Drug
A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.
FamitinibDrug
A VEGFR inhibitor administered orally per the protocol.
Fat Module Formula for Special Medical PurposesDietary supplement
This nutritional formulation is composed primarily of medium-chain triglycerides (MCT), which are metabolized by the liver to induce nutritional ketosis, thereby significantly elevating circulating levels of beta-hydroxybutyrate (BHB).
Trastuzumab (or biosimilar)Drug
An anti-HER2 antibody, via intravenous (into the vein) infusion or subcutaneous per protocol.
9MW2821Drug
A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.
Disitamab Vedotin (RC48)Drug
A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.
Treatment of physician's choice (TPC)Drug
Treatment of physician's choice (TPC), such as nab-paclitaxel, carboplatin, gemcitabine, capecitabine, vinorelbine, eribulin, etc., with specific dosages and administration methods determined at the investigator's discretion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: The observation period related to this endpoint is up to 36 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Breast cancer institute of Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.